[IEEE-bhpjobs] Fwd: Explore Global Healthcare Trends at Aug. 15 Biotech Forum

[Esther Lumsdon]

---------- Forwarded message ----------
From: CED's.Biotech.Forum at mailroc.acgiaa.net
<CED's.Biotech.Forum at mailroc.acgiaa.net>
Date: Wed, 26 Jul 2006 17:15:03 UT
Subject: Explore Global Healthcare Trends at Aug. 15 Biotech Forum



Biotech Forum: "Impact of Globalization in Healthcare"
 Date: August 15, 2006
 Time: 6:30-9 pm (6-6:30 on-site registration)
 Location: North Carolina Biotechnology Center, RTP, NC
 Fees: Special rate for this event -- $10 pre-registration online; $15 on-site
 Contact: zmansfield at cednc.org
 Register: https://secure.cednc.org/my_ced/index.php/event/1640

Global healthcare systems today are growing at an unsustainable rate
while consumers on a worldwide basis are demanding more and better
healthcare services. Integration and access to information, innovation
and entrepreneurship will play a growing role in aligning escalating
demand with discovery and delivery of affordable, quality healthcare.

Multinationals, western private equity funds and large companies have
earmarked billions of dollars to invest in global ventures to build
financial services, biotech, healthcare and technology industries
around the world.

At the August 15th Biotech Forum, join industry thought leaders from
diverse perspectives to listen and discuss how globalization and
innovation is changing the healthcare (and life sciences) industry,
and how we can benefit from such globalization now.

Panelists include:

Victor Dzau, MD, Chancellor for Health Affairs, Duke University;
President and CEO, Duke University Health System
Art Pappas, Managing Partner, Pappas Ventures
Dan Pelino, General Manager, IBM Healthcare and Life Sciences Industry
John Ratliff, Executive Vice President and Chief Financial Officer,
Quintiles Transnational Corp.
Grace Ueng (panel moderator), Founder and CEO, Savvy Marketing Group



Biotech Forum Reception Sponsor:

IBM Healthcare and Life Sciences



Space is limited, so register online today!

The August Biotech Forum is co-hosted by CED and the NC Chinese
Business Association (NCCBA - www.nc-cba.org), with support from NCBIO
and the North Carolina Biotechnology Center.

Panelist Biographies:

 Victor Dzau, MD, Chancellor for Health Affairs, Duke University;
President and CEO, Duke University Health System

 Victor J. Dzau, MD, was appointed Chancellor for Health Affairs at
Duke University and President and CEO of the Duke University Health
System effective July 1, 2004. He is also James B. Duke Professor of
Medicine and Director of Molecular and Genomic Vascular Biology at
Duke. Most recently, Dr. Dzau was the Hersey Professor of the Theory
and Practice of Physic (Medicine) at Harvard Medical School, Chairman
of the Department of Medicine at Brigham and Women's Hospital, and
Physician-in-Chief and Director of Research at Brigham and Women's
Hospital, Boston. Prior to his work at Harvard and Brigham and
Women's, he served as Arthur Bloomfield Professor and Chairman of the
Department of Medicine at Stanford. Dr. Dzau's academic interests are
in cardiovascular translational research and mission-based education.
His laboratory has studied the molecular and genetic mechanisms of
cardiovascular disease and applied genomic and gene transfer
technologies to develop novel therapeutic approaches. His work on the
renin angiotensin system (RAS) paved the way for the contemporary
understanding of RAS in cardiovascular disease and the development of
RAS inhibitors (e.g. ACE inhibitor) as therapeutics. He pioneered gene
therapy for vascular disease, being the first to introduce DNA decoy
molecules to block transcriptions as gene therapy in vivo. Two of his
discoveries E2F decoy and nitric oxide synthase gene therapy are now
being evaluated in clinical trials.

Art Pappas, Managing Partner, Pappas Ventures

 Art Pappas has over 30 years of experience as a pharmaceutical and
biotechnology industry executive and venture capital investor in life
science companies. Prior to founding Pappas Ventures in 1994, he held
senior level positions at several multinational pharmaceutical
companies. He was an executive member of the board of directors of
Glaxo Holdings plc, for which he was responsible for international
operations including research, development and manufacturing. Pappass
previously was Vice President of Commercial Operations for Abbott
International Ltd., and he held various executive positions with
Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the
United States and internationally. Among the companies for which he
currently serves as a director are: AtheroGenics (Nasdaq: AGIX), which
conducted a successful IPO in 2000, BrainCells, Genstruct, and
Syntonix Pharmaceuticals. He is chairman of CoLucid Pharmaceuticals.
Art previously served as a board observer at Variagenics (Nasdaq:
NUVO), which completed a successful IPO in 2000, and he was directly
responsible for investments in Gene Logic (Nasdaq: GLGC), which went
public in 1997, and Novalon Pharmaceutical, which was acquired at a
substantial premium by a publicly held Swedish company. He also
previously served on the boards of Embrex (Nasdaq: EMBX), Quintiles
Transnational and Valentis (Nasdaq: VLTS).

Dan Pelino, General Manager, IBM Healthcare and Life Sciences Industry

 Dan Pelino leads a team developing the latest information technology
solutions and services, establishing partnerships, and overseeing IBM
investments in the healthcare, pharmaceutical and life sciences
markets. He works closely with leaders in healthcare and life
sciences, including public and private healthcare providers and
payers, and biotech and pharmaceutical companies, to help them
leverage IBM capabilities to innovate and grow. During his career, he
has held several positions in marketing and sales. He is involved in
many organizations, including the Advisory Board of Western Kentucky
University, Chicagoland Chamber of Commerce, Illinois Governor's
Transition Team Streamlining Government Committee, the Board of
Directors for Teach for America. Dan received a Masters Degree in
Organizational Communications and a Bachelor of Science undergraduate
degree in Business Administration and Public Relations from Western
Kentucky University.

John Ratliff, Executive Vice President and Chief Financial Officer,
Quintiles Transnational Corp.

 John Ratliff came to Quintiles Transnational in 2004 as Chief
Financial Officer. As Chairman of the Financial Operations
subcommittee of the Executive Committee, Ratliff brings to his role a
strong financial background and experience with large multinational
companies. Prior to joining Quintiles, Ratliff worked for Acterna, the
world's second largest provider of communications test solutions for
telecommunications and cable network operators. Before moving to
Acterna in 2000, he worked 19 years at IBM, holding several positions
of increasing responsibility. Ratliff's most recent positions at IBM
included Vice President for Finance and Planning, Latin America, Vice
President for Finance and Planning, PC Company, and Assistant
Controller. Ratliff received his bachelor's degree in industrial and
systems engineering from the Georgia Institute of Technology in
Atlanta and his MBA from Duke University.

Grace Ueng, Founder and CEO, Savvy Marketing Group

 Grace Ueng is a proven executive with over 20 years of broad business
experience with a foundation built on classical consumer packaged
goods brand management leveraged into the sales and marketing of high
growth consumer and business to business products. Ueng has served as
a consultant with international strategy leader Bain & Company and
then worked in the consumer marketing division of Time Inc. After
receiving her MBA from Harvard Business School, she managed five major
national household brands with leaders General Mills and Clorox. She
then held executive leadership positions with five high growth
technology ventures which collectively generated over $1 billion in
investor returns. Ueng is Founder and CEO of Savvy Marketing Group LLC
in Research Triangle Park, a consulting firm that uses proven
methodologies to help new ventures maximize their chances for success.
Clients include companies in consumer products/services,
healthcare/life sciences, and information technology sectors.

To unsubscribe from this list, click here.
To globally unsubscribe from all CED communications, click here.
Please allow 72 hours for your request to be processed.